losartan has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beilin, LJ; Croft, KD; Proudfoot, JM; Puddey, IB | 1 |
| Kumova, TA; medvedev, iN; Simonenko, VB | 1 |
1 trial(s) available for losartan and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
| Article | Year |
|---|---|
[Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hypertension; Losartan; Male; Metabolic Syndrome; Platelet Activating Factor | 2008 |
1 other study(ies) available for losartan and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Binding Sites; Binding, Competitive; Biphenyl Compounds; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Irbesartan; Lipoproteins, LDL; Losartan; Monocytes; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Tetrazoles | 2003 |